Selective behavioral alterations on addition of a 4′ -phenyl group to cocaine

NeuroReport

Volumn 7, Issue 2, 1996, Pages 617-621

  Seale, Thomas W ^a   Niekrasz, Iwona ^a   Chang, Fengchun ^b   Singh, Satendra ^b   Basmadjian, Garo P ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Behavior; Cocaine; Cocaine antagonist; Dopamine transporter; Lethality; Locomotor activity; Seizures; Stimulants

Indexed keywords

COCAINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; BINDING SITE; CONTROLLED STUDY; DOPAMINE UPTAKE; LOCOMOTION; MALE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; CARRIER PROTEINS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CONVULSANTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; NARCOTICS; NERVE TISSUE PROTEINS; PAPIO; PROTEIN BINDING;

EID: 0029995210     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199601310-00058     Document Type: Article

References (25)

1. Kuhar MJ, Ritz MC and Boja JW. Trends Neurosci 14, 299-302 (1991).
2. Woods JW, Winger GW and France CP. Reinforcing and discrimination Stimulus effects of cocaine: analysis of pharmacological mechanisms. In: Fisher S, Raskin A and Uhlenhuth EH, eds. Cocaine: Clinical and Biobehavioral Aspects. New York: Oxford University Press, 1987: 21-65.
3. Witkin JM. Neurosci Biobehav Rev 18, 121-142 (1994).
4. Tolliver BK and Carney JM. Pharmacol Biochem Behav 50, 163-169 (1995).
5. Reith MEA, Meisler BE, Sershen H et al. Biochem Pharmacol 35, 1123-1129 (1986).
6. George FR. Psychopharmacology 104, 307-311 (1991).
7. Ritz MC, Lamb RJ, Goldberg SR et al. Science 237, 1219-1223 (1987).
8. Xu M, Hu X-T, Cooper DC et al. Cell 79, 945-955 (1994).
9. Neisewander JL, O'Dell LE and Redmond JC. Brain Res 671, 201-212 (1995).
10. Church WH, Justice JBJ and Byrd LD. Eur J Pharmacol 139; 345-348 (1987).
11. Di Chiara G and Imperato A. Proc Natl Acad Sci USA 85, 5274-5278 (1988).
12. Ritz MC and George FR. J Pharmacol Exp Ther 264, 1333-1343 (1993).
13. Terry P, Witkin JM and Katz JL. J Pharmacol Exp Ther 270, 1041-1048 (1994).
14. Reith MEA, Meisler BE and Lajtha A. Pharmacol Biochem Behav 23, 831-836 (1985).
15. Reith MEA, Kim SS and Lajtha A. J Biol Chem 261, 7300-7305 (1986).
16. Withers NW, Pulvirenti L, Koob GF et al. J Clin Psychopharmacol 15, 63-78 (1995).
17. Rothman RB. Life Sci 46, PL17-PL21 (1990).
18. Simoni D, Stoelwinder J, Kozikowski IP et al. J Med Chem 36, 3975-3977 (1993).
19. Carroll FI, Mascarella SW, Kuzemko MA et al. J Med Chem 37, 2865-2873 (1994).
20. Deutsch HM and Schweri MM. Life Sci 55, PL115-PL120 (1994).
21. Hemby SE, Co C, Reboussin D et al. J Pharmacol Exp Ther 273, 656-666 (1995).
22. Porrino LJ, Davies HM and Childers SR. J Pharmacol Exp Ther 272, 901-910 (1995).
23. Logan L, Seale TW and Carney JM. Pharmacol Biochem Behav 24, 1281-1286 (1986).
24. Seale TW, Carney JM, Rennert OM et al. Pharmacol Biochem Behav 26, 381-387 (1987).
25. Madras BK, Spealman RD, Fahey MA et al. Mol Pharnacol 36, 518-524 (1989).